Stoke Space closed an initial $1 billion Series E on September 8, bringing total capital raised to $2.3 billion. Its fully reusable Nova Pathfinder is targeting early 2027 for a first orbital launch, with the larger Nova Block 2 scheduled for 2029.
Anthropic's $400 million acquisition of Coefficient Bio marks a new class of biotech buyer: frontier AI labs paying for models and talent instead of clinical assets. Here is the exit math, the risk, and what it means for founders and investors.
Elbit Systems folded its autonomous drones and ground vehicles into FUSE, a unit built on the Dominion-X operating system. The pitch is that coordinating hundreds of machines, not building them, is the hard part, and that layer carries the margin.
Harvey's $550M round at a $15.5B valuation is the first real price on the AI-agent economy in professional services. The bull case is penetration and product depth; the bear case is a multiple that outran the business.
Sweden’s four-reactor SMR program rests on a consortium of reactor vendor, builder and financiers. The syndicate structure is the template; the missing final investment decision is the risk.
Sceye's ST1 airship flew 15,000 km from New Mexico to Japan in 13 days, then handed live mobile broadband to ordinary phones through SoftBank's core network. It marks the shift from experiment to network infrastructure, and raises the question of who certifies it.
Windfall Bio was one of the best-funded bets on turning methane into fertilizer. It scaled production, passed field trials, then ran out of runway. The collapse says less about methane-eating microbes than about the cost of the machines around them.
A two-year-old Santa Clara startup left stealth with $100M, eight robots and a contrarian bet: solve industrial labor one task at a time, and let the operating data compound.